{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:51:54Z","timestamp":1776873114197,"version":"3.51.2"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00228-022-03412-0","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:43:28Z","timestamp":1671281008000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Imprecision in adverse event reports following immunization against HPV in Japan and COVID-19 in the USA, UK, and Japan\u2014and the effects of vaccine hesitancy and government policy"],"prefix":"10.1007","volume":"79","author":[{"given":"Yasuko","family":"Inokuma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Kneller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"key":"3412_CR1","unstructured":"Inokuma I, Kneller R (n.d.) Features in vaccine adverse event reporting generated through the system: insights from the Japanese and U.S. reporting systems, in preparation"},{"key":"3412_CR2","unstructured":"Asahi-shimbun (2013) Serious adverse event reported following HPV vaccination to junior high school students. https:\/\/www.asahi.com\/area\/tokyo\/articles\/MTW1303261300002.html. Accessed Nov 2022"},{"issue":"2","key":"3412_CR3","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M et al (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8(2):e191\u2013e203","journal-title":"Lancet Glob Health"},{"key":"3412_CR4","unstructured":"Cancer Today \u2013 IARC (2020) Estimated number of new cases in worldwide, both sexes, all ages. https:\/\/gco.iarc.fr\/today\/online-analysis-table. Accessed Nov 2022"},{"key":"3412_CR5","unstructured":"ICO\/IARC (2019) Information centre on HPV and cancer, Human papillomavirus and related diseases report.\u00a0https:\/\/hpvcentre.net\/statistics\/reports\/JPN.pdf"},{"key":"3412_CR6","doi-asserted-by":"publisher","unstructured":"Simms KT et al (2020) Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health 5(4):e223\u2013e234.\u00a0https:\/\/doi.org\/10.1016\/S2468-2667(20)30010-4","DOI":"10.1016\/S2468-2667(20)30010-4"},{"issue":"5","key":"3412_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.canep.2015.08.001","volume":"39","author":"Y Motoki","year":"2015","unstructured":"Motoki Y et al (2015) Increasing trends in cervical cancer mortality among young Japanese women below the age of 50 years: an analysis using the Kanagawa population-based Cancer Registry, 1975\u20132012. Cancer Epidemiol 39(5):700\u2013706","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"3412_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10147-014-0723-1","volume":"20","author":"A Morimoto","year":"2015","unstructured":"Morimoto A et al (2015) Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination. Int J Clin Oncol 20(3):549\u2013555","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"3412_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10147-017-1188-9","volume":"23","author":"M Sawada","year":"2018","unstructured":"Sawada M et al (2018) HPV vaccination in Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their opinions toward the vaccine. Int J Clin Oncol 23(1):121\u2013125","journal-title":"Int J Clin Oncol"},{"key":"3412_CR10","unstructured":"Ministry of Health, Labour and Welfare, A joint meeting of the Vaccine Adverse Reactions Review Committee (VARRC) (2016) https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000147016.pdf. Accessed Nov 2022"},{"key":"3412_CR11","doi-asserted-by":"crossref","unstructured":"Hanley SJ, Sharon JB et al (2015) HPV vaccination crisis in Japan. The Lancet 385(9987):2571","DOI":"10.1016\/S0140-6736(15)61152-7"},{"key":"3412_CR12","unstructured":"Ministry of Health Labour and Welfare (2010) Special urgent grant to enhance HPV vaccine etc. https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/kekkaku-kansenshou28\/pdf\/vaccine_kouhukin_enchou.pdf, Accessed Nov 2022"},{"key":"3412_CR13","doi-asserted-by":"crossref","unstructured":"Tsuda K et al (2016) Trends of media coverage on human papillomavirus vaccination in Japanese newspapers. Clin Infect Dis\u00a0ciw647","DOI":"10.1093\/cid\/ciw647"},{"issue":"1","key":"3412_CR14","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/s12889-019-7097-2","volume":"19","author":"T Okuhara","year":"2019","unstructured":"Okuhara T et al (2019) Newspaper coverage before and after the HPV vaccination crisis began in Japan: a text mining analysis. BMC Public Health 19(1):770","journal-title":"BMC Public Health"},{"key":"3412_CR15","unstructured":"WORLD HEALTH ORGANIZATION et al (2013) GACVS safety update on HPV vaccines. https:\/\/www.who.int\/vaccine_safety\/committee\/topics\/hpv\/130619HPV_VaccineGACVSstatement.pdf. Accessed Nov\u00a02020"},{"key":"3412_CR16","unstructured":"National Attorneys Assocication for the HPV Vaccines Lawsuits in Japan (2013) http:\/\/hpv-yakugai.net. Accessed Nov 2022"},{"issue":"3","key":"3412_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijgo.2013.09.009","volume":"123","author":"L Denny","year":"2013","unstructured":"Denny L et al (2013) Safety of HPV vaccination: a FIGO statement. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 123(3):187\u2013188","journal-title":"International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics"},{"key":"3412_CR18","unstructured":"The 23th Vaccination Sub-Committee Meeting (2016) Investigative Committee on Adverse Reactions, Health Sciences Council, Ministry of Health, Labour, and Welfare. (Also known as the Sobue Study.)"},{"key":"3412_CR19","doi-asserted-by":"crossref","unstructured":"Hosono A (2018)\u00a0No association between HPV vaccine and reported post-vaccination symptoms in Japanese young women: results of the Nagoya study. Papillomavirus Res 5:96\u2013103","DOI":"10.1016\/j.pvr.2018.02.002"},{"key":"3412_CR20","unstructured":"Ministry of Health, Labour and Welfare, Corresponding to the routine vaccination of HPV vaccine (recommendation) (2013) Health Service Bureau 0614\u20131, Director of Health Service Bureau. https:\/\/www.mhlw.go.jp\/bunya\/kenkou\/kekkaku-kansenshou28\/pdf\/kankoku_h25_6_01.pdf. Accessed Nov 2022"},{"key":"3412_CR21","unstructured":"Ministry of Health Labour and Welfare (2013) Minutes of VARRC"},{"issue":"3","key":"3412_CR22","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/vaccines8030362","volume":"8","author":"M Sekine","year":"2020","unstructured":"Sekine M et al (2020) Japan\u2019s ongoing crisis on HPV vaccination. Vaccines 8(3):362","journal-title":"Vaccines"},{"key":"3412_CR23","unstructured":"Ministry of Health Labour and Welfare (2021) Minutes of VARRC"},{"key":"3412_CR24","unstructured":"Ministry of Health, Labour and Welfare, Q&A for COVID-19 vaccination. https:\/\/www.cov19-vaccine.mhlw.go.jp\/qa\/0053.html. Accessed Nov 2022"},{"issue":"1","key":"3412_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10147-015-0869-5","volume":"21","author":"T Egawa-Takata","year":"2016","unstructured":"Egawa-Takata T et al (2016) Human papillomavirus vaccination of the daughters of obstetricians and gynecologists in Japan. Int J Clin Oncol 21(1):53\u201358","journal-title":"Int J Clin Oncol"},{"key":"3412_CR26","unstructured":"Vaccine Adverse Reactions Review Committee Meeting Material convened on (2018) https:\/\/www.mhlw.go.jp\/file\/05-Shingikai-10601000-Daijinkanboukouseikagakuka-Kouseikagakuka\/0000199232.pdf. Accessed Nov 2022"},{"key":"3412_CR27","unstructured":"Ministry of Health Labour and Welfare (2021)\u00a0Summary of anaphylaxis cases following immunization against the new corona virus"},{"key":"3412_CR28","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention (2020) Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine \u2014 United States, December 14\u201323. https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7002e1.htm. Accessed Nov 2022","DOI":"10.15585\/mmwr.mm7002e1"},{"key":"3412_CR29","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) (2021) Coronavirus vaccine - weekly summary of Yellow Card reporting. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting. Accessed Nov 2022"},{"key":"3412_CR30","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (1994)\u00a0Clinical safety data management: definitions and standards for expedited reporting E2A"},{"issue":"6","key":"3412_CR31","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1111\/cas.14406","volume":"111","author":"S Nakagawa","year":"2020","unstructured":"Nakagawa S et al (2020) Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan. Cancer Sci 111(6):2156","journal-title":"Cancer Sci"},{"key":"3412_CR32","unstructured":"Ministry of Health Labour and Welfare (2018) Form to report AEFI. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/saishin.pdf#search=%27%E5%89%AF%E5%8F%8D%E5%BF%9C+%E6%A7%98%E5%BC%8F%27. Accessed Nov 2022"},{"key":"3412_CR33","unstructured":"Food and Drug Administration (2021) Comirnaty and Pfizer-BioNTech COVID-19 vaccine. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/comirnaty-and-pfizer-biontech-covid-19-vaccine. Accessed Nov 2022"},{"key":"3412_CR34","unstructured":"Food and Drug Administration (2021) Moderna COVID-19 vaccine. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/moderna-covid-19-vaccine. Accessed Nov 2022"},{"key":"3412_CR35","unstructured":"Medicines and Healthcare products Regulatory Agency (2020) Oxford University\/AstraZeneca COVID-19 vaccine approved. https:\/\/www.gov.uk\/government\/news\/uk-medicines-regulator-gives-approval-for-first-uk-covid-19-vaccine. Accessed Nov 2022"},{"key":"3412_CR36","unstructured":"Ministry of Health Labour and Welfare (2021) Current R&D of Covid-19 vaccines. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000121431_00223.html. Accessed Nov 2022"},{"key":"3412_CR37","unstructured":"Ministry of Health Labour and Welfare (2021)\u00a0Amendment of Administrative notice of COVID-19 vaccination (Directive)"},{"key":"3412_CR38","unstructured":"Ministry of Health Labour and Welfare (2021) Administrative notice of system to vaccination and distribution of COVID-19 vaccine manufactured by AstraZeneca"},{"key":"3412_CR39","doi-asserted-by":"crossref","unstructured":"IGUCHI, Toyotaka et al (2021) Cumulative adverse event reporting of anaphylaxis after mRNA COVID-19 vaccine (Pfizer-BioNTech) injections in Japan: the first-month report. Drug Saf 1\u20136","DOI":"10.1007\/s40264-021-01104-9"},{"key":"3412_CR40","unstructured":"Ministry of Health Labour and Welfare (2021) Summary of anaphylaxis cases reported from Marketing Authorization Holders following immunization against the new corona virus"},{"key":"3412_CR41","unstructured":"Ministry of Health Labour and Welfare (2021) Adverse Event Report from Healthcare Professionals based on Preventive Vaccination Act"},{"key":"3412_CR42","doi-asserted-by":"crossref","unstructured":"Klein, Nicola P et al (2021) Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA","DOI":"10.1001\/jama.2021.15072"},{"key":"3412_CR43","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA) (2021) Coronavirus vaccine - weekly summary of Yellow Card reporting"},{"key":"3412_CR44","unstructured":"Ministry of Health Labour and Welfare (2021) VARRC meeting material 1\u20137\u20131: situation on AE reporting.\u00a0https:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-kousei_284075.html. Accessed Dec\u00a02021"},{"key":"3412_CR45","doi-asserted-by":"publisher","unstructured":"Larson HJ, de Figueiredo A, Zhao XH et al (2016) The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine 12:295\u2013301.\u00a0https:\/\/doi.org\/10.1016\/j.ebiom.2016.08.042. Accessed Mar\u00a02021","DOI":"10.1016\/j.ebiom.2016.08.042"},{"issue":"6","key":"3412_CR46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/vaccines9060662","volume":"9","author":"R Okubo","year":"2021","unstructured":"Okubo R et al (2021) COVID-19 vaccine hesitancy and its associated factors in Japan. Vaccines 9(6):662","journal-title":"Vaccines"},{"key":"3412_CR47","unstructured":"The New York Times (2021) Tracking coronavirus vaccinations around the world. https:\/\/www.nytimes.com\/interactive\/2021\/world\/covid-vaccinations-tracker.html. Accessed Nov 2022"},{"key":"3412_CR48","unstructured":"Medicines and Healthcare Products Regulatory Agency (2021) Coronavirus (COVID-19) vaccines adverse reactions -a weekly report covering adverse reactions to approved COVD-19 vaccines. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions. Accessed Nov 2022"},{"key":"3412_CR49","unstructured":"Ministry of Health, Labour and Welfare (2021) VARRC meetings.\u00a0https:\/\/www.mhlw.go.jp\/stf\/shingi\/shingi-kousei_284075.html. Accessed Dec\u00a02021"},{"key":"3412_CR50","doi-asserted-by":"crossref","unstructured":"Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B, Brighton Collaboration Working Group on Anaphylaxis (2010) Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine 28:4487\u20134498","DOI":"10.1016\/j.vaccine.2010.04.041"},{"key":"3412_CR51","unstructured":"Vaccine adverse event reporting system report an adverse event to VAERS (n.d.)\u00a0https:\/\/www.vaers.hhs.gov\/reportevent.html. Accessed Dec\u00a02021"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03412-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T08:05:18Z","timestamp":1674720318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03412-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3412"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03412-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"28 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}